Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

179.56 -6.07 (-3.27%)
Streaming Delayed Price Updated: 2:58 PM EST, Jan 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
57 58 Next >
News headline image
Biotech Is Coming Back, Can The Run Last? ↗
The rally can be attributed to lower interest rates and seasonal factors from the end of Q4 through January. But recently some major biopharmaceutical deals have supported the rally. 
Via Talk Markets
News headline image
$1000 Invested In This Stock 20 Years Ago Would Be Worth $7,200 Today ↗
 
Via Benzinga
News headline image
2 Popular Stocks to Avoid Like the Plague in 2024 and Beyond ↗
These stocks aren't worth the risk. 
Via The Motley Fool
News headline image
S&P 500's Hidden Gems: 27 Stocks With 30%+ Upside Potential According To Wall Street Analysts Targets ↗
Fifty-six percent of S&P 500 companies have shown positive performance in 2023 and 44% retreated Moderna Inc. (NASDAQ: MRNA) offers the highest upside potential (58%). 
Via Benzinga
Topics Stocks
News headline image
The Latest Analyst Ratings for Biogen ↗
 
Via Benzinga
News headline image
Comparative Study: Biogen And Industry Competitors In Biotechnology Industry ↗
 
Via Benzinga
News headline image
Here's How Much $1000 Invested In Biogen 20 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Why This Biogen Analyst Is Turning Bullish On Alzheimer's Treatment Prospects ↗
Biogen Inc (NASDAQ: BIIB) has been in focus due to its treatment for early-stage Alzheimer’s disease. 
Via Benzinga
News headline image
Doing Your Holiday Shopping? These Stocks Might Make Great Gifts
No matter which holiday you're planning gifts for, Christmas, Hanukkah, or some other occasion, there may be one great gift idea you haven't thought of yet. 
Via MarketBeat
Topics Bonds
News headline image
Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others ↗
Recent advancements in Alzheimer's disease treatments targeting the removal of toxic proteins (white matter) from the brain have sparked a renewed interest in developing vaccines to combat this  
Via Benzinga
News headline image
Industry Comparison: Evaluating Biogen Against Competitors In Biotechnology Industry ↗
 
Via Benzinga
News headline image
Expert Ratings for Biogen ↗
 
Via Benzinga
News headline image
Looking Into Biogen's Recent Short Interest ↗
 
Via Benzinga
News headline image
Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning ↗
Biotech companies are edging closer to finding the answers behind Alzheimer's disease. 
Via Investor's Business Daily
News headline image
Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review ↗
The major indexes ended long win streaks. Datadog led earnings winners. 
Via Investor's Business Daily
News headline image
The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks? ↗
The real competitive battle is about to begin, and it will last a long time. 
Via The Motley Fool
News headline image
Here's How Much You Would Have Made Owning Biogen Stock In The Last 15 Years ↗
 
Via Benzinga
News headline image
Assessing Biogen's Performance Against Competitors In Biotechnology Industry ↗
 
Via Benzinga
News headline image
These Analysts Revise Their Forecasts On Biogen After Q3 Results ↗
Biogen Inc (NASDAQ: BIIB) reported better-than-expected third-quarter earnings. 
Via Benzinga
News headline image
Thoughts For Thursday: Staying On Top - Barely ↗
The stock market continues to be full of worry, but is managing to stay on top this week, so far. It is worth noting that yesterday's close brought levels back to those of a month ago. 
Via Talk Markets
News headline image
Biogen (BIIB) Q3 2023 Earnings Call Transcript ↗
BIIB earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
News headline image
Biogen Revises Annual Forecast As Reata M&A And Alzheimer's Drug Expenses Hit Bottomline, Stock Slides ↗
Biogen Inc (NASDAQ: BIIB) posted Q3 FY23 sales of $2.53 billion, beating the con 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Compared To Estimates, Biogen Inc. Q3 Earnings: A Look At Key Metrics ↗
Biogen Inc. reported $2.53 billion in revenue for the quarter ended September 2023. 
Via Talk Markets
News headline image
US Stocks Set To Open Flat After Hot 7-Day Rally: Traders Sharpen Focus On Powell's Speech, Disney Earnings ↗
Stock futures indicate a subdued opening on Wednesday after several consecutive gains in major averages. Traders are eagerly awaiting Federal Reserve Chair Jerome Powell’s speech for insights into... 
Via Benzinga
Topics Economy
News headline image
Biogen Tops Earnings Forecasts, But Cuts Profit Outlook As Leqembi Expenses Mount ↗
The company shares in the profits and sales related to Alzheimer's treatment, Leqembi. 
Via Investor's Business Daily
News headline image
3 Biotech Moonshots to Bet on the Future of Health ↗
Thanks to their potential blockbuster drugs, these three biotech stocks may yield huge returns for patent investors willing to take the risk. 
Via InvestorPlace
Topics Intellectual Property
News headline image
Biogen Appoints Monish Patolawala to its Board of Directors
Accomplished executive brings deep expertise leading global financial organizations and overseeing successful business transformation 
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen Pulls Prothena Into A Steep Dive On Mixed Results For Alzheimer's Treatment ↗
Both companies are working on under-the-skin injections for Alzheimer's treatment. 
Via Investor's Business Daily
News headline image
Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional Analyses of Clarity AD at The Clinical Trials On
From Biogen Inc.
Via GlobeNewswire
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
57 58 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.